READ-ONLY DIGITIZATION RESULT
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Nat Commun · 2026-Mar-14 · PMID 41826281
Panel B质量警告待 EXE 对齐验证
Progression-free Survival
Fig. 5. Progression-free survival by metastatic disease at baseline. Kaplan–Meier estimate in subgroups with metastatic disease ( A ) and without metastatic disease ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 1.0000 | 0.0000 | 100.0000 | 109 | 29 |
| 1 | 2 | 0.0604 | 0.9487 | 1.9920 | 94.8718 | 139 | 39 |
| 1 | 3 | 0.0624 | 0.9436 | 2.0584 | 94.3590 | 140 | 40 |
| 1 | 4 | 0.0644 | 0.9436 | 2.1247 | 94.3590 | 141 | 40 |
| 1 | 5 | 0.0664 | 0.9436 | 2.1911 | 94.3590 | 142 | 40 |
| 1 | 6 | 0.0684 | 0.9436 | 2.2575 | 94.3590 | 143 | 40 |
| 1 | 7 | 0.0704 | 0.9436 | 2.3239 | 94.3590 | 144 | 40 |
| 1 | 8 | 0.0724 | 0.9436 | 2.3903 | 94.3590 | 145 | 40 |
| 1 | 9 | 0.0744 | 0.9436 | 2.4567 | 94.3590 | 146 | 40 |
| 1 | 10 | 0.0765 | 0.9436 | 2.5231 | 94.3590 | 147 | 40 |
| 1 | 11 | 0.0785 | 0.9436 | 2.5895 | 94.3590 | 148 | 40 |
| 1 | 12 | 0.0805 | 0.9436 | 2.6559 | 94.3590 | 149 | 40 |
| 1 | 13 | 0.0825 | 0.9436 | 2.7223 | 94.3590 | 150 | 40 |
| 1 | 14 | 0.0845 | 0.9436 | 2.7887 | 94.3590 | 151 | 40 |
| 1 | 15 | 0.0865 | 0.9436 | 2.8551 | 94.3590 | 152 | 40 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-24T15:13:30+00:00 |